Quantcast

Industry news that matters to you.  Learn more

SAP and Technical University Munich Decode Human Proteome and Make Data Available for Biomedical Research

SAP AG (NYSE: SAP) and Technical University Munich (TUM) recently announced ProteomicsDB, a new offering based on the SAP HANA® platform that stores protein and peptide identifications from mass spectrometry-based experiments. The proteomic data assembled in the new offering resulted in the identification of proteins mapping to over 18,000 human genes. This represents 90 percent coverage of the human proteome. Data stored and analyzed within ProteomicsDB can be used in basic and biomedical research for discovering therapeutic targets and developing new drugs as well as enhanced diagnosis methods.

As personalized medicine is on the rise, the healthcare field is discovering the opportunities of big data analysis. The result of a joint project between the TUM Chair of Proteomics and Bioanalytics, SAP and the SAP Innovation Center, ProteomicsDB is a major step forward in human proteomics. It currently contains more than 11,000 datasets from human cancer cell lines, tissues and body fluids and enables real-time analysis of this highly dimensional data and creates instant value by allowing to test analytical hypothesis.

ProteomicsDB is based on the SAP HANA for rapid data mining and visualization. It has been built to enable public sharing of mass spectrometry-based proteomic datasets as well as to allow users to access and review data prior to publication. The database is backed with 50 TB of storage, 2 TB RAM and 160 processing units. A direct interface to the programming languages L, C++ and R allows more flexible calculations than are possible with standard SQL. The Web interface is built on a JavaScript framework for HTML5 and optimized for Google Chrome but also available under Internet Explorer and Mozilla Firefox. An easy-to-use and fast Web interface allows users to browse and upload data to the repository as well as browsing the human proteome, including protein level information such as protein function and expression.

ProteomicsDB will be available free of charge. The database will be a valuable asset for researchers in the field of life sciences as well as for the pharmaceutical and biotechnology industry. Insights from analyzing the inherent datasets can be used in biomedical research and for example in developing new drugs that operate in a more targeted way without adversely influencing other cellular processes, helping to reduce side effects.

“The vast amounts of molecular data generated in biomedical research increasingly challenge the ability of scientists to see ‘the forest for the trees,” said Prof. Dr. Bernhard Kuster of TUM. “ProteomicsDB is a significant step ahead in our research aiming at a better understanding of human disease and more informed future treatments. The software helps us and others to store, integrate and analyze experimental data in real time, allowing us to study more complex biological systems at greater depth than previously possible.”

Source: SAP

NextBio Announces Translational Medicine Partnership with Sanofi

NextBio recently announced a multi-year collaboration with Sanofi (NYSE:SNY) aimed at using NextBio Clinical to incorporate patient omics and clinical data into Sanofi’s drug research and development, as part of Sanofi’s Translational Medicine for Patients (TM4P) program.

Elsevier Launches Web-Based Pathway Studio and Adds New Molecular Data from Its Biology Journals to Boost Early Discovery Research

Elsevier, a world-leading provider of scientific, technical and medical information products and services, recently announced the launch of a web-based version of Pathway Studio, a research solution for biologists. Additionally, Pathway Studio now incorporates biological data from Elsevier’s biology journals in addition to journals obtained through collaboration with third-party publishers. The addition of this data to Pathway Studio results in a resource that is unparalleled in depth and coverage of molecular interactions with supporting evidence. The new web-based version broadly extends access to researchers to reveal new insights and to assist with critical decision making.

“Currently, molecular facts are scattered in individual articles and researchers must gather and integrate these to advance new discovery,” said Jaqui Mason, Product Development Director for Biology Products at Elsevier. “Pathway Studio presents these facts in a graphical context to help researchers assemble biological models that can be applied to target discovery programs, identify potential diagnostics, and reposition drugs. The new content included in Pathway Studio can expose a more complete picture in biology, which reduces risk, increases efficiency, and ultimately improves success rate whether it’s bringing a new drug to market or exploring a theory.”

“Incorporation of facts from Elsevier’s biology journals into Pathway Studio, as well as building a pipeline of fresh data through our collaboration with third-party publishers, enables us to deliver additional value to our portfolio of solutions across biology, chemistry, and medicine in order to better serve the needs of customers in early discovery and biology researchers,” said Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group. “Offering a web-based version of Pathway Studio has allowed us to streamline common tasks and make the benefit of this content accessible to a broader and more general user-base.”

The new web-based Pathway Studio adds additional early discovery capability to Elsevier’s suite of life science information solutions which include Reaxys, the leading chemistry discovery engine, PharmaPendium which supports regulatory and safety activities, TargetInsights, a biological literature search system for early discovery and Quosa, which automates literature management workflows with applications in pharmacovigilance and medical affairs. This suite effectively delivers complementary solutions spanning early discovery, pre-clinical, clinical and post-launch workflows.

Source: Elsevier

Accelerated Cure Project for Multiple Sclerosis Partners with Leading Organizations in an Alliance to Find New MS Treatments

Accelerated Cure Project for Multiple Sclerosis (ACP-MS) recently announced the launch of Orion Bionetworks, a multi-institution cooperative alliance that is unlocking the power of shared data and predictive modeling to help transform our understanding of diseases such as multiple sclerosis (MS) and accelerate the search for cures.

Orion Bionetworks is a program of the Marin Community Fund, a nonprofit 501(c)(3) corporation, and is funded by Janssen Research & Development, LLC, a New Jersey-based pharmaceutical company, which has provided a $5.4 million scientific sponsorship as part of its Healthy Minds program for the first phase of this effort. Initially, this cooperative alliance will focus on integrating clinical, biomarker and imaging data with rich real-world patient data from existing, independent databases of over 7,000 people with MS into a causal computational disease model.

“We are delighted to collaborate with such a dynamic group of innovators to launch Orion Bionetworks,” said Robert McBurney, Chief Executive Officer of ACP-MS. “Orion is demonstrating that a predictive disease modeling alliance that uses real-world patient data can have an unprecedented ability to drive toward better treatments and, ultimately, cures for multiple sclerosis and other devastating brain disorders. Our involvement in the alliance is a direct result of the remarkable effort that ACP-MS, the staff of 10 MS clinics nationwide, and people with MS and related diseases have made to create the open-access ACP Repository of biosamples and data.”

ACP-MS will be contributing to the alliance its expertise in MS and experience with its innovative approach to highly collaborative research in MS and related disorders. Additionally, it will provide extensive clinical and epidemiological data from over 3,000 participants in the Repository program along with the almost 300 million molecular data points returned, to date, to the Repository database from the many academic and industrial research groups that have undertaken research with the Repository’s biosamples and data.

ACP-MS will work closely with other leading organizations in patient care, computational modeling and translational research participating in the alliance, including the Institute for Neurosciences at Brigham and Women’s Hospital, GNS Healthcare, MetaCell, and PatientsLikeMe. As part of Orion Bionetworks, ACP-MS will have access to the combined datasets and expertise of all members of the alliance and is receiving support from Orion to undertake data-mining activities in search of new knowledge that will lead to improved treatments and cures for MS and related disorders.

“Complex diseases such as MS require novel research approaches and large scale collaborations,” said Benjamin Greenberg, MD, MHS, Deputy Director of the MS Program at the University of Texas Southwestern Medical Center and ACP-MS Advisory Board Member. “The ACP Repository serves as an outstanding resource and its partnership with Orion will undoubtedly yield extremely useful insights into this complicated disease.”

Additional information on the Orion Bionetworks and partnership opportunities is available on the organization’s website, www.orionbionetworks.org.

Source: Business Wire

NextBio Teams With Emory University for Cancer Biomarker Discovery

NextBio recently announced a partnership with Emory University and its Winship Cancer Institute using genomic data to identify unique biomarkers and treatments for patients with multiple myeloma. The centerpiece of the partnership is a translational research study that will use NextBio Clinical to interpret molecular data from patients with multiple myeloma, with the ultimate goal of making new discoveries that will improve the care of patients with refractory and relapsed forms of myeloma. These forms of myeloma, a plasma cell cancer that constitutes about 1% of all cancers in the United States, have been particularly challenging to treat.